Saxagliptin hydrate [945667-22-1]
Cat# T0178-50mg
Size : 50mg
Marca : TargetMol
Saxagliptin hydrate
Contact us for more batch information
Purity:99.8%
Resource Download
COA HPLC HNMR
Saxagliptin hydrate
Catalog No. T0178Cas No. 945667-22-1
Saxagliptin hydrate (Onglyza hydrate) is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. Pack Size | |
---|---|
5 mg | |
10 mg | |
25 mg | |
50 mg | |
100 mg | |
500 mg | |
1 mL x 10 mM (in DMSO) |
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
Description | Saxagliptin hydrate (Onglyza hydrate) is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM). |
In vitro | In vitro, saxagliptin inhibits FBS-, insulin- and IGF1-induced ERK phosphorylation and cell proliferation, in both MSC and MC3T3E1 preosteoblasts. In the absence of growth factors, saxagliptin has no effect on ERK activation or cell proliferation. In both MSC and MC3T3E1 cells, saxagliptin in the presence of FBS inhibits Runx2 and osteocalcin expression, type-1 collagen production and mineralization, while increasing PPAR-gamma expression[4]. |
In vivo | Saxagliptin exerts direct beneficial effects on the arterial wall in an animal model of type 2 diabetes by increasing NO availability and improving antioxidant status. Saxagliptin reverses vascular hypertrophic remodeling and ameliorates NO availability in small arteries from db/db mice through the abrogation of NAD(P)H oxidase-driven eNOS uncoupling and by reducing the action of cyclooxygenase-1-derived vasoconstrictors downregulating the expression of thromboxane-prostanoid receptors[2]. DPP-4 inhibition with saxagliptin also improves pancreatic β-cell function in postprandial and fasting states, and decreases postprandial glucagon concentration[3]. |
Cell Research | Sub-confluent cells are serum-starved overnight and then incubated with 1.5 or 15 μM saxagliptin and/or FBS (1%), insulin (5 ng/mL) or IGF1 (10-8 M) for 24 h (effects on cell proliferation) or 1 h (effects on signal transduction mechanisms). (Only for Reference) |
Alias | Onglyza hydrate, BMS-477118 hydrate |
Molecular Weight | 333.43 |
Formula | C18H25N3O2·H2O |
Cas No. | 945667-22-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 61 mg/mL (182.9 mM) H2O: 1 mg/mL (3 mM) Ethanol: 61 mg/mL (182.9 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
DMSO
|
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each
animal weighs 20 g, and the dosage volume is 100 μL. A total of
10 animals were administered, and the formula you used is 5%
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSO
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSO
main solution, add 300 μLPEG300
mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2O
mix well and clarify.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Keywords
Saxagliptin hydrateDPPglucagon-likec-mycBMS-477118glucagonβ-cateninBMS 477118SaxagliptinBMS477118insulinproliferationOnglyza Hydratep-AKTInhibitorpeptide-1BMS-477118 HydratediabetesDipeptidyl PeptidaseDPP-4Saxagliptin HydrateBMS477118 HydrateinhibitBMS 477118 Hydrate